How does Gilead Sciences (GILD) make money?

Gilead Sciences (GILD) generates revenue primarily from Products, Other HIV, which accounted for 77.8% of total revenue in TTM through Q1 2026. The company reported $29.73B in revenue and converted 31% of it into net profit, equivalent to roughly $9.22B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Gilead Sciences (GILD)?

Gilead Sciences (GILD) reported a gross profit margin of 79.4% in TTM through Q1 2026, equivalent to $23.59B in gross profit on $29.73B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Gilead Sciences (GILD)?

Gilead Sciences (GILD) reported an operating profit margin of 38.3% in TTM through Q1 2026, equivalent to $11.38B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Gilead Sciences (GILD)?

Gilead Sciences (GILD) reported a net profit margin of 31% in TTM through Q1 2026, equivalent to $9.22B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Gilead Sciences (GILD) profitable?

Yes. Gilead Sciences (GILD) reported $9.22B in net income for TTM through Q1 2026, with a net profit margin of 31%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Gilead Sciences (GILD) invest in research and development?

Gilead Sciences (GILD) invested $5.79B in research and development during TTM through Q1 2026, roughly 19.5% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Gilead Sciences (GILD) spend on capital expenditures?

Gilead Sciences (GILD) spent $576.00M on capital expenditures (CapEx) during TTM through Q1 2026, roughly 1.9% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Gilead Sciences (GILD) generate?

Gilead Sciences (GILD) generated $10.23B in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 34.4%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of Gilead Sciences (GILD)?

Gilead Sciences (GILD) had an effective tax rate of 14.1% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of Gilead Sciences (GILD)?

Gilead Sciences (GILD) reports revenue across 6 reportable product segments, led by Products, Other HIV at 77.8% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

Where does Gilead Sciences (GILD) generate most of its revenue?

UNITED STATES is the largest geographic market for Gilead Sciences (GILD), accounting for 71.1% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How Gilead Sciences Makes Money: 2026 Visual Revenue Map

Gilead Sciences (GILD) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported May 7, 2026).

Gilead Sciences (GILD) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Gilead Sciences (GILD) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Products, Other HIV	$23.14B	77.8%
Cell Therapy Products, Total Cell Therapy Product Sales	$2.40B	8.1%
Trodelvy	$1.64B	5.5%
Liver Disease	$867.91M	2.9%
Other Products, Total Other product sales	$858.09M	2.9%
Veklury	$822.06M	2.8%
Total	$29.73B	100%

Products, Other HIV$23.14B
Cell Therapy Products, Total Cell Therapy Product Sales$2.40B
Trodelvy$1.64B
Liver Disease$867.91M
Other Products, Total Other product sales$858.09M
Veklury$822.06M
Total$29.73B

Gilead Sciences (GILD) Revenue by Geography — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for Gilead Sciences (GILD), TTM through Q1 2026
Region	Revenue (USD)	% of total
UNITED STATES	$21.13B	71.1%
Europe	$5.12B	17.2%
Other International	$3.48B	11.7%
Total	$29.73B	100%

UNITED STATES
Europe
Other International
Total

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, Gilead Sciences (GILD) reports revenue across 6 operating segments; the largest segment was Products, Other HIV at 77.8%, followed by Cell Therapy Products, Total Cell Therapy Product Sales (8.1%) and Trodelvy (5.5%). Separately, by end-market geography, UNITED STATES accounted for 71.1% of revenue, followed by Europe (17.2%) and Other International (11.7%).

Frequently asked questions

Data & methodology

Gilead Sciences (GILD) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation